Henry Schein, Inc. (LON:0L3C)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 7.36B +23.8% |
| Revenue (ttm) | 10.29B +6.5% |
| Net Income | 304.93M +3.6% |
| EPS | 2.60 +10.3% |
| Shares Out | n/a |
| PE Ratio | 24.13 |
| Forward PE | 15.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2 |
| Open | 89.47 |
| Previous Close | 89.08 |
| Day's Range | 88.84 - 89.53 |
| 52-Week Range | 62.29 - 92.50 |
| Beta | 0.81 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Henry Schein
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, di... [Read more]
Financial Performance
In 2025, Henry Schein's revenue was $13.18 billion, an increase of 4.03% compared to the previous year's $12.67 billion. Earnings were $398.00 million, an increase of 2.05%.
Financial numbers in USD Financial StatementsNews
Henry Schein price target raised to $100 from $86 at Barclays
Barclays raised the firm’s price target on Henry Schein (HSIC) to $100 from $86 and keeps an Overweight rating on the shares. The firm upped estimates citing the company’s “strong”…
Henry Schein price target raised to $104 from $97 at Barrington
Barrington analyst Michael Petusky raised the firm’s price target on Henry Schein (HSIC) to $104 from $97 and keeps an Outperform rating on the shares. The company’s Q2 beat included…
Henry Schein price target raised to $109 from $97 at Baird
Baird analyst Jeff Johnson raised the firm’s price target on Henry Schein (HSIC) to $109 from $97 and keeps an Outperform rating on the shares. The firm updated its model…
Henry Schein price target raised to $86 from $82 at Mizuho
Mizuho analyst Steven Valiquette raised the firm’s price target on Henry Schein (HSIC) to $86 from $82 and keeps a Neutral rating on the shares.
Henry Schein price target raised to $94 from $89 at UBS
UBS analyst Kevin Caliendo raised the firm’s price target on Henry Schein (HSIC) to $94 from $89 and keeps a Neutral rating on the shares. Henry Schein delivered a solid…
Henry Schein price target raised to $95 from $84 at Stifel
Stifel raised the firm’s price target on Henry Schein (HSIC) to $95 from $84 and keeps a Hold rating on the shares.
Henry Schein price target raised to $112 from $100 at Citi
Citi raised the firm’s price target on Henry Schein (HSIC) to $112 from $100 and keeps a Buy rating on the shares.
Henry Schein Earnings Call Transcript: Q2 2026
Q2 2026 saw strong sales and margin growth, with global sales up 6.7% and non-GAAP EPS up 15.5%. Full-year guidance was raised, driven by robust performance across dental, medical, specialty, and technology segments, and ongoing value creation initiatives.
Henry Schein Earnings release: Q2 2026
Henry Schein released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Henry Schein Slides: Q2 2026
Henry Schein has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Henry Schein Quarterly report: Q2 2026
Henry Schein has published its Q2 2026 quarterly earnings report on August 4, 2026.
Henry Schein Slides: Corporate presentation
Henry Schein has posted slides in relation to its latest quarterly earnings report, which was published on August 4, 2026.
Henry Schein raises 2026 non-GAAP EPS view to $5.29-$5.39 from $5.23-$5.37
2026 EPS consensus $5.34. Raises 2026 revenue growth view to 4.5%-5.5% from 3%-5%, consensus $13.75B. 2025 revenue was $13.18B.
Henry Schein reports Q2 non-GAAP EPS $1.27 , consensus $1.24
Reports Q2 revenue $3.5B, consensus $3.37B. “We delivered strong sales performance and margin improvement in the second quarter, driven by sustained momentum across our businesses and solid operationa...
Henry Schein Reports Strong Second Quarter 2026 Financial Results and Raises FY2026 Guidance
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, today reported financial resu...
Henry Schein Stock (HSIC) Falls as Three Senior Executives Leave the Company
The stock has been treading water for five years.
Henry Schein creates HSLT, announces leadership transitions
Henry Schein (HSIC) announced that it is creating the Henry Schein Leadership Team, HSLT, to replace its Executive Management Committee. The Company will also integrate its global supply chain organiz...
Henry Schein Announces Leadership Transitions
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) announced today that it is creating the Henry Schein Leadership Team (HSLT) to replace its Executive Management Committee. The Compan...
Henry Schein price target raised to $95 from $91 at Piper Sandler
Piper Sandler analyst Jason Bednar raised the firm’s price target on Henry Schein (HSIC) to $95 from $91 and keeps an Overweight rating on the shares. The firm notes Henry…
Henry Schein price target raised to $89 from $85 at UBS
UBS raised the firm’s price target on Henry Schein (HSIC) to $89 from $85 and keeps a Neutral rating on the shares.
Henry Schein to Webcast Second Quarter 2026 Conference Call on Tuesday, August 4, 2026, at 8:00 a.m. ET
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will ...
BMO starts ‘execution-dependent’ Henry Schein with a Market Perform
As previously reported, BMO Capital initiated coverage of Henry Schein (HSIC) with a Market Perform rating and $85 price target With a new CEO yet to establish investor credibility, and…
Henry Schein initiated with a Market Perform at BMO Capital
BMO Capital analyst Vik Chopra initiated coverage of Henry Schein (HSIC) with a Market Perform rating and $85 price target
Henry Schein partners with GoTu for dental workforce support
Henry Schein (HSIC) and GoTu Technology, a dental talent marketplace, announced a new strategic partnership designed to help dental practices address ongoing staffing challenges and maintain continuit...
GoTu and Henry Schein Announce Strategic Partnership to Strengthen Dental Workforce Support Nationwide
MIAMI, June 30, 2026 /PRNewswire/ -- GoTu Technology, the nation's leading dental talent marketplace, and Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to of...